AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7065555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30252681 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon J-pouch (CJP)
Number of subjects: 336
Study 30252681 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis (SEA)
Number of subjects: 336
Study 30252681 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight colorectal anastomosis (SCA)
Number of subjects: 336
Study 30032816 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 419
Study 30032816 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 419
Study 25615707 — intervention group
Group type: EXPERIMENTAL
Intervention: FUEL Your Life intervention
Number of subjects: 362
Study 25615707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study 25012565 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN+GM-CSF
Number of subjects: 58
Study 22958354 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Assessment Program (CHAP), a one-off health check, and the Ask Health Diary
Number of subjects: 0
Study 22958354 — intervention group
Group type: EXPERIMENTAL
Intervention: Education component of the intervention delivered as part of the school curriculum
Number of subjects: 0
Study 20856184 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine extended release (75 to 325 mg daily)
Number of subjects: 161
Study 17586338 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-based coping leaflet
Number of subjects: 162
Study 17586338 — intervention group
Group type: COMPARATOR
Intervention: Standard information (Control)
Number of subjects: 162
Study 16292117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 15
Study 11809349 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medical management
Number of subjects: 733
Study 10189453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-saturated images
Number of subjects: 140
Study 10189453 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital image subtraction
Number of subjects: 140
Study 10189453 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic agent
Number of subjects: 140
Study 10189453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric meal
Number of subjects: 140
Study 10189453 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 140
Study 7756056 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogs
Number of subjects: 21
Study 7756056 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogs + Org OD 14 (Tibolone, Livial)
Number of subjects: 21
Study 1326708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate (E2V)
Number of subjects: 55
Study 1326708 — intervention group
Group type: COMPARATOR
Intervention: 2 mg oestradiol valerate combined with 1 mg cyproterone acetate (E2V+CPA)
Number of subjects: 55
Study 1326708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 2860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD)
Number of subjects: 109
Study 2860453 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Number of subjects: 109
Study 2860453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned SWD)
Number of subjects: 109
Study 29208679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (150 million)
Number of subjects: 120
Study 29208679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29208679 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction present at baseline
Number of subjects: 120
Study 27501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Cannula 4 liters per minute
Number of subjects: 500
Study 27501599 — intervention group
Group type: COMPARATOR
Intervention: Oxygen Mask 5 liters per minute
Number of subjects: 500
Study 26999966 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Number of subjects: 0
Study 26999966 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (40 mg methylprednisolone)
Number of subjects: 0
Study 23113988 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge home visit
Number of subjects: 126
Study 23113988 — intervention group
Group type: COMPARATOR
Intervention: Structured, hospital-based interview (Control)
Number of subjects: 126
Study 21252702 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g/kg body weight)
Number of subjects: 24
Study 21252702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18288974 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine+lamivudine+lopinavir/ritonavir
Number of subjects: 64
Study 18288974 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir+lamivudine+efavirenz
Number of subjects: 64
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-particle formulations of ICSs
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid conjugation of ICSs
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS with longer serum half-life
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS with increased protein binding and high systemic clearance
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced oropharyngeal deposition and prodrug administration
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal ICS characteristics
Number of subjects: 0
Study 17063660 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS with high plasma protein binding and rapid clearance
Number of subjects: 0
Study 14499200 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeled walker
Number of subjects: 19
Study 14499200 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard walker
Number of subjects: 19
Study 14499200 — intervention group
Group type: COMPARATOR
Intervention: Unassisted walking
Number of subjects: 19
Study 14499200 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeled walker with laser attachment
Number of subjects: 19
Study 10953973 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly CHOP (8 cycles)
Number of subjects: 63
Study 10953973 — intervention group
Group type: COMPARATOR
Intervention: Dose-escalated CHOP (6 cycles with cyclophosphamide 1.5 g/m2 and doxorubicin 70 mg/m2)
Number of subjects: 63
Study 9543399 — intervention group
Group type: EXPERIMENTAL
Intervention: HAB (tissue adhesive)
Number of subjects: 61
Study 9543399 — intervention group
Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 61
Study 9543399 — intervention group
Group type: EXPERIMENTAL
Intervention: HAB
Number of subjects: 61
Study 8181400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise program (Group 2) for five weeks
Number of subjects: 26
Study 8181400 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 26
Study 3286363 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of acarbose
Number of subjects: 8
Study 3286363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29685011 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids in combination with ursodesoxycholic acid
Number of subjects: 120
Study 29685011 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids only (Control)
Number of subjects: 120
Study 27533307 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 219
Study 27533307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 24884779 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Prevention Approach for CardioMetabolic Risk (PPA CMR)
Number of subjects: 0
Study 24884779 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 22490643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin prophylaxis
Number of subjects: 99
Study 22490643 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 19888948 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. once every 4 weeks (Q4W)
Number of subjects: 296
Study 19888948 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. twice every week (Q2W)
Number of subjects: 296
Study 19888948 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (once weekly or Q2W)
Number of subjects: 296
Study 18829800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 60
Study 18829800 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 60
Study 16102549 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microg EE/day)
Number of subjects: 0
Study 16102549 — intervention group
Group type: COMPARATOR
Intervention: Transdermal patch (20 microg EE/day)
Number of subjects: 0
Study 16102549 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (30 microg EE)
Number of subjects: 0
Study 11880765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group using diaries to measure sunscreen application
Number of subjects: 0
Study 11880765 — intervention group
Group type: COMPARATOR
Intervention: Control group not using diaries
Number of subjects: 0
Study 7631288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) administered orally while fasting
Number of subjects: 12
Study 7631288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) administered orally after a standard meal
Number of subjects: 12
Study 7631288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) administered intravenously
Number of subjects: 12
Study 2921098 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (MK 733) 20 mg and 40 mg daily for 104 weeks
Number of subjects: 19
Study 31904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia along with general anaesthesia
Number of subjects: 101
Study 31904749 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 101
Study 28348100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate, neutral‐pH, low‐GDP PD fluid (Physioneal)
Number of subjects: 78
Study 28348100 — intervention group
Group type: COMPARATOR
Intervention: Standard lactate‐buffered PD fluid (Dianeal)
Number of subjects: 78
Study 26706793 — intervention group
Group type: EXPERIMENTAL
Intervention: Video fluoroscopy
Number of subjects: 50
Study 23543341 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise training (12-week program under supervision)
Number of subjects: 99
Study 23543341 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 99
Study 22132709 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 211
Study 22132709 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine plus bepanthenol cream (standard practice)
Number of subjects: 211
Study 19240683 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (lymphatic application)
Number of subjects: 24
Study 19240683 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphatic drainage
Number of subjects: 24
Study 17976098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 195
Study 15089819 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine (2 mg, BID) + duloxetine (40 mg, BID)
Number of subjects: 16
Study 15089819 — intervention group
Group type: COMPARATOR
Intervention: tolterodine (2 mg, BID) + duloxetine placebo (BID)
Number of subjects: 16
Study 11573019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour biweekly training sessions for 1 year (total 60 hours) for managers
Number of subjects: 302
Study 11573019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 302
Study 9587128 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate tablets (45 mg, three times a day)
Number of subjects: 18
Study 9587128 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (three times a day)
Number of subjects: 18
Study 7888741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemakers on
Number of subjects: 11
Study 7888741 — intervention group
Group type: COMPARATOR
Intervention: Pacemakers off or turned to minimum rate
Number of subjects: 11
Study 2669092 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g L-tryptophan
Number of subjects: 10
Study 2669092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g L-tryptophan
Number of subjects: 10
Study 2669092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2669092 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (both doses)
Number of subjects: 10
Study 2669092 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (all doses)
Number of subjects: 10
Study 796836 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 1015
Study 796836 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1015
Study 31309975 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 370
Study 31309975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 31309975 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 370
Study 31090869 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable pulmonary artery pressure monitoring system
Number of subjects: 1087
Study 31090869 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1087
Study 28282524 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure intervention (2-session coping skills intervention)
Number of subjects: 699
Study 28282524 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 699
Study 26366068 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 μg
Number of subjects: 0
Study 26366068 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 0
Study 26366068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23903649 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein‐phosphopeptide amorphous‐calcium‐phosphate (CPP‐ACP)
Number of subjects: 0
Study 23903649 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer (GI)
Number of subjects: 0
Study 23903649 — intervention group
Group type: COMPARATOR
Intervention: Control (original‐lesion control, intra‐oral controls)
Number of subjects: 0
Study 22153532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g bid for 10 days)
Number of subjects: 0
Study 22153532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium bicarbonate 1 g bid for 10 days)
Number of subjects: 0
Study 19898719 — intervention group
Group type: COMPARATOR
Intervention: Acetone-containing bonding agent (control group)
Number of subjects: 146
Study 19898719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 146
Study 19898719 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 146
Study 19898719 — intervention group
Group type: COMPARATOR
Intervention: 37% orthophosphoric acid (control group)
Number of subjects: 146
Study 17998456 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg twice daily (group 1)
Number of subjects: 355
Study 17998456 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg twice daily (group 2)
Number of subjects: 355
Study 17998456 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin continued (group 3)
Number of subjects: 355
Study 14726422 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione aerosol (300 or 450 mg, thrice daily for 14 days)
Number of subjects: 23
Study 12487386 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapies prescribed as part of the trial
Number of subjects: 93
Study 12487386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse clinical events (e.g., dermatological, gastrointestinal symptoms)
Number of subjects: 93
Study 9772328 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination (both vaccines administered simultaneously)
Number of subjects: 0
Study 9772328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine (single injection of both vaccines mixed)
Number of subjects: 0
Study 9772328 — intervention group
Group type: COMPARATOR
Intervention: Monovalent vaccines (each vaccine administered alone)
Number of subjects: 0
Study 8209214 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with sharp instruments combined with pocket flushing
Number of subjects: 8
Study 8209214 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with blunt plastic curettes and pocket flushing
Number of subjects: 8
Study 8209214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket flushing alone
Number of subjects: 8
Study 2590611 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg intravenous)
Number of subjects: 9
Study 2590611 — intervention group
Group type: COMPARATOR
Intervention: Sodium salicylate (600 mg intravenous)
Number of subjects: 9
Study 2590611 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control for aspirin infusion)
Number of subjects: 9
Study 184978 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel (80 units once weekly or 80 units twice weekly)
Number of subjects: 0
Study 184978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 31610099 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (10 mg rivaroxaban tablet)
Number of subjects: 28
Study 31331789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg up to 150 mg every 2 weeks for COMBO I & II or 150 mg every 2 weeks for LONG TERM)
Number of subjects: 4489
Study 31331789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4489
Study 31331789 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for COMBO I and LONG TERM or ezetimibe for COMBO II)
Number of subjects: 4489
Study 28481893 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic psychodynamic online intervention (12 weeks)
Number of subjects: 664
Study 28481893 — intervention group
Group type: COMPARATOR
Intervention: Control group (augmented treatment as usual)
Number of subjects: 664
Study 25920961 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon gas device
Number of subjects: 0
Study 25920961 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen device
Number of subjects: 0
Study 23970700 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-1
Number of subjects: 2694
Study 23970700 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2
Number of subjects: 2694
Study 23970700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HSV-1 and HSV-2
Number of subjects: 2694
Study 23970700 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegativity to both HSV-1 and HSV-2
Number of subjects: 2694
Study 23970700 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and racial differences
Number of subjects: 2694
Study 21777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fipronil, amitraz and (S)-methoprene (CERTIFECT™)
Number of subjects: 0
Study 21777735 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated dogs)
Number of subjects: 0
Study 19195785 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-oxycodone
Number of subjects: 87
Study 19195785 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 87
Study 19195785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 17037953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music listening intervention delivered by a board‐certified music therapist
Number of subjects: 63
Study 17037953 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 63
Study 12643328 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Hirudin (i.v. bolus of 0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Number of subjects: 15
Study 12643328 — intervention group
Group type: COMPARATOR
Intervention: ASA (325 mg)
Number of subjects: 15
Study 12643328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of ASA and PEG-Hirudin
Number of subjects: 15
Study 12643328 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Hirudin alone
Number of subjects: 15
Study 12643328 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Hirudin (0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Number of subjects: 15
Study 12643328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of PEG-Hirudin and ASA
Number of subjects: 15
Study 10704630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 0% stenosis
Number of subjects: 1200
Study 10704630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 10‐69% stenosis
Number of subjects: 1200
Study 10704630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 70‐100% stenosis
Number of subjects: 1200
Study 10704630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients under 70 years of age
Number of subjects: 1200
Study 10704630 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterized patients
Number of subjects: 1200
Study 10704630 — intervention group
Group type: COMPARATOR
Intervention: Non‐smoking controls without angina
Number of subjects: 1200
Study 9344296 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS) ambulation training sessions using the Parastep 1 system (32 sessions)
Number of subjects: 16
Study 10124337 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized physical therapists
Number of subjects: 26
Study 3748494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin sodium
Number of subjects: 360
Study 3748494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephapirin sodium
Number of subjects: 360